1. Home
  2. JBDI vs TLPH Comparison

JBDI vs TLPH Comparison

Compare JBDI & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JBDI
  • TLPH
  • Stock Information
  • Founded
  • JBDI 1983
  • TLPH 2005
  • Country
  • JBDI Singapore
  • TLPH United States
  • Employees
  • JBDI N/A
  • TLPH N/A
  • Industry
  • JBDI
  • TLPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • JBDI
  • TLPH Health Care
  • Exchange
  • JBDI Nasdaq
  • TLPH Nasdaq
  • Market Cap
  • JBDI 13.6M
  • TLPH 13.4M
  • IPO Year
  • JBDI 2024
  • TLPH 2011
  • Fundamental
  • Price
  • JBDI $0.65
  • TLPH $0.70
  • Analyst Decision
  • JBDI
  • TLPH Strong Buy
  • Analyst Count
  • JBDI 0
  • TLPH 2
  • Target Price
  • JBDI N/A
  • TLPH $4.50
  • AVG Volume (30 Days)
  • JBDI 248.2K
  • TLPH 65.0K
  • Earning Date
  • JBDI 12-03-2024
  • TLPH 11-13-2024
  • Dividend Yield
  • JBDI N/A
  • TLPH N/A
  • EPS Growth
  • JBDI N/A
  • TLPH N/A
  • EPS
  • JBDI N/A
  • TLPH N/A
  • Revenue
  • JBDI $9,394,000.00
  • TLPH $281,000.00
  • Revenue This Year
  • JBDI N/A
  • TLPH N/A
  • Revenue Next Year
  • JBDI N/A
  • TLPH N/A
  • P/E Ratio
  • JBDI N/A
  • TLPH N/A
  • Revenue Growth
  • JBDI N/A
  • TLPH N/A
  • 52 Week Low
  • JBDI $0.60
  • TLPH $0.61
  • 52 Week High
  • JBDI $39.41
  • TLPH $1.61
  • Technical
  • Relative Strength Index (RSI)
  • JBDI N/A
  • TLPH 36.13
  • Support Level
  • JBDI N/A
  • TLPH $0.66
  • Resistance Level
  • JBDI N/A
  • TLPH $0.79
  • Average True Range (ATR)
  • JBDI 0.00
  • TLPH 0.08
  • MACD
  • JBDI 0.00
  • TLPH -0.02
  • Stochastic Oscillator
  • JBDI 0.00
  • TLPH 17.24

About JBDI JBDI Holdings Limited Ordinary Shares

JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. Its products include Reconditioned and new steel drums, plastic drums, carboys and IBCs.

About TLPH Talphera Inc.

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Share on Social Networks: